There are many positives that may come from the proposed amendments to the Therapeutic Goods Amendment (2017 Measures No. 1) Bill, such as increased post-marketing surveillance and tougher penalties and sanctions for detected regulatory violations.
Some key players are concerned however with the Bill’s impact on the advertising of therapeutic goods to consumers.
The abolition of the pre-approval of advertisements for complementary and over-the-counter medicines, which currently prevents misleading advertisements is of key concern.
On January 23, 2018 The SMH delivered the following article titled:
"Public health groups slam removal of pre-approval of complementary medicine advertisements"